OARS funding Cancer

Honoring the legacy of Paul A. Marks, MD, President Emeritus of Memorial Sloan-Kettering Cancer Center and a distinguished scientist, the Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or clinical research. The Paul Marks Prize is awarded every other year to up to three investigators. The first recipients were named in 2001. The winners will present their work at a scientific symposium at Memorial Sloan-Kettering Cancer Center and share a cash award of $150,000. Nominations are now being accepted for the 2013 Paul Marks Prize for Cancer Research. Nominees must be age 45 or younger on the date of the submission deadline, April 30, 2013. Prize winners will be announced in Fall 2013.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions with expertise and innovative strategies for developing research and mentoring opportunities for undergraduate students from backgrounds underrepresented in biomedical research to submit applications for 6 month planning grants for the NIH Building Infrastructure Leading to Diversity (BUILD) initiative. The BUILD initiative aims to increase the diversity of the NIH-funded workforce by supporting collaborative programs that include novel approaches for enhancing undergraduate education, training, and mentorship, as well as infrastructure support and faculty development to facilitate those approaches. BUILD planning grants are intended to help institutions develop the necessary partnerships and infrastructure needed to be competitive for the BUILD initiative.

The Childhood Brain Tumor Foundation (CBTF) is soliciting grant applications for the calendar year 2013. There will be two categories of awards: Pediatric Brain Tumor Grant Awards Our standard grant request for pediatric brain tumor awards will continue as usual. We anticipate funding up to three (3) research proposals that are a maximum of two years in duration. Funding requests cannot exceed $30,000/year or a maximum of $60,000 over the course of the award. Pilocytic Astrocytoma Award We have specific funds for one, 1-year research proposal related to pilocytic astrocytoma. The funding request for this award can be up to a maximum of $50,000.

CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of junior faculty who exemplify the role of teacher-scholars through outstanding research, excellent education and the integration of education and research within the context of the mission of their organizations. Such activities should build a firm foundation for a lifetime of leadership in integrating education and research. NSF encourages submission of CAREER proposals from junior faculty members at all CAREER-eligible organizations and especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply.

The NIH encourages institutions that seek to engage undergraduate students in innovative mentored research training programs to submit applications for cooperative agreement awards through the NIH Building Infrastructure Leading to Diversity (BUILD) initiative, one of three new Common Fund initiatives that together aim to enhance diversity in the biomedical, behavioral, clinical, and social sciences research workforce. Addressing a major leakage point in the research workforce pipeline, BUILD awards are intended to support the design and implementation of innovative programs, strategies and approaches to transform undergraduate research training and mentorship. BUILD awards will also support institutional and faculty development to further strengthen undergraduate research training environments.

The AACR Basic Cancer Research Fellowships are open to postdoctoral and clinical research fellows working at an academic, medical, or research institution who will be in the first, second, or third year of their postdoctoral training at the start of the grant term. The research proposed for funding may be in any area of basic cancer research. The fellowships provide one-year grants of $50,000-45,000 to support the salary and benefits of the Fellow while working on a mentored basic cancer research project. A partial amount of funds may be designated for nonpersonnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

The AACR-Millennium Fellowship in Lymphoma Research represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct lymphoma-based research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to lymphoma. The fellowship provides a one-year grant of $55,000 to support the salary and benefits of the fellow while working on mentored lymphoma-related research. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project and other research expenses. It is anticipated that three fellowships will be funded.

The Postdoctoral Fellowship Award supports exceptionally talented recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral training and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented scientists who have demonstrated that they are the "best and brightest" of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research. Under this award mechanism, the postdoctoral fellow is considered the Principal Investigator (PI) and, as such, should write the project narrative, training plan, and other application components with appropriate guidance from the mentor. While the PI is not required to have previous experience in breast cancer research, the proposed project and training must focus on breast cancer. Applications must emphasize the PI's high potential for success in becoming an independent breast cancer researcher based on his/her qualifications, achievements (including first-author publications), and letters of recommendation. The mentor (or co-mentor, if applicable) must possess the appropriate expertise and experience in breast cancer, to include publications and active peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the PI's research and training. If the mentor is not an experienced breast cancer researcher, then formal co-mentorship by an established breast cancer researcher is required. The application must include information about the mentor's experience in conducting innovative research and how he/she intends to support the PI's endeavors in breast cancer. 

This year, National Lung Cancer Partnership will award multiple two-year, $100,000 research grants to post-doctoral fellows and junior faculty in support of our vision to double lung cancer survival by 2022. The purpose of this Grant Program is to drive research forward that will lead to increasing survival rates for lung cancer patients, while ensuring that young investigators have the resources needed for them to succeed as lung cancer researchers.

Grants distributed from Alex's Lemonade Stand Foundation are designed to fill critical voids in current pediatric cancer research. All applications are reviewed by the appropriate Grant Review Boards and approved by the ALSF Board of Directors.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

The Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to carcinoid tumors or pancreatic neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to carcinoid tumor or pancreatic neuroendocrine tumor research.

The Kure It-AACR Grant for Kidney Cancer Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to kidney cancer patients. Applicants with experience in other areas of cancer or biomedical/health science research who have promising ideas and approaches that can be applied to kidney cancer research are encouraged to apply.

The following programs have due dates that fall between October 1 - 25, 2013, and these dates are being revised due to the Federal  government shutdown. These revised dates apply whether the proposal is being submitted via the NSF FastLane System or  Grants.gov. Due to compressed proposal deadlines resulting from the shutdown, proposers are advised that they may experience a  delay when contacting IT Help Central with technical support questions. Frequently asked questions regarding these date changes  are available on the Resumption of Operations page on the NSF website at: http://www.nsf.gov/bfa/dias/policy/postshutdown.jsp. 

This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies and technical/analytical validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been significantly evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, early detection and screening, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will not be reviewed.